Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Melanoma, Cutaneous Malignant × Paclitaxel × Clear all

Phase

Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 127 Breast Neoplasms 127 Ovarian Neoplasms 77 Fallopian Tube Neoplasms 43 Lung Neoplasms 42 Carcinoma, Ovarian Epithelial 29 Uterine Cervical Neoplasms 27 Parkinson Disease 4, Autosomal Dominant Lewy Body 27 Endometrial Neoplasms 25 Triple Negative Breast Neoplasms 23 Neoplasms 20 Neoplasm Metastasis 20 Esophageal Neoplasms 19 Stomach Neoplasms 18 Esophageal Squamous Cell Carcinoma 14 Adenocarcinoma of Lung 13 Carcinoma 12 Brenner Tumor 11 Recurrence 10 Urinary Bladder Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 8 Head and Neck Neoplasms 8 Peritoneal Neoplasms 7 Inflammatory Breast Neoplasms 5 Carcinoma, Squamous Cell 5 Adenocarcinoma, Bronchiolo-Alveolar 5 Adenocarcinoma 5 Melanoma 4 Carcinoma, Ductal, Breast 4 Adenocarcinoma Of Esophagus 4

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Vitamin D 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Dacarbazine 1 Cholecalciferol 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06743126 2026-04-13

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡